Evidence map›Paper›PMID 41278240›Full record

ArticleEClinicalMedicine2025

A multidisciplinary approach to assessing the impact of local therapy in pediatric bone sarcoma patients and survivors: a cross-sectional study of adverse events and health-related quality of life.

Leonie G Tigelaar, Lianne M Haveman, Willem P Bekkering, Harm Van Tinteren, Heleen Maurice-Stam, Hinke Van der Hoek, Martha A Grootenhuis, Laura R Beek, Christel D Rohrich, Irene L B Oude Lansink and 9 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Association of primary congenital glaucoma with quality of life in children and their families.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Leonie G TigelaarPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Lianne M HavemanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Willem P BekkeringPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Harm Van TinterenPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Heleen Maurice-StamPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Hinke Van der HoekPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Martha A GrootenhuisPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Laura R BeekPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Christel D RohrichDepartment of Pediatric Rehabilitation, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
Irene L B Oude LansinkDepartment of Pediatric Rehabilitation, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
Max M Van NoeselPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Wouter J W KollenPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Willemijn Plieger-van SolkemaDutch National Childhood Cancer Association (Parent Advocacy Group), Utrecht, the Netherlands.
Lizz Van der HeijdenPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Jos A M BramerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Michiel A J Van de SandePrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Hendrik W B SchreuderPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Johannes H M MerksPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pediatric bone sarcoma patients undergo intensive treatment including life-changing local therapy, which results in a high burden of adverse events (AEs) and reduced health-related quality of life (HR-QoL). Given this multidimensional impact, optimal follow-up care requires a multidisciplinary expert team. We setup a multidisciplinary follow-up clinic with carousel consultations-including pediatric oncologists/late effects specialists, orthopedic surgeons, rehabilitation physicians, physical therapists, and psychologists-to screen for local therapy-related issues using standardized measurements. In addition to enhancing care, this clinic enables the study of a nationwide cohort. Methods: This cross-sectional study included patients diagnosed with pediatric bone sarcoma from 2003 onwards who completed local therapy and subsequent treatment, and attended the multidisciplinary follow-up clinic between 18 November 2021 and 7 March 2024. Patient satisfaction was assessed using a modified satisfaction questionnaire, and care output was documented based on healthcare professionals' actions following the consultations using a predefined action list. AEs and HR-QoL of the patients seen at the multidisciplinary clinic were evaluated using the Common Terminology Criteria for Adverse Events, Henderson classification, and PedsQL™ Generic Core Scales. Findings: Satisfaction with the provided care was reported by 99% (135/136) of patients. Healthcare professionals documented 182 actions, with counseling for identified patient needs being the most frequent. AEs were present in 96% (138/144) of patients, including moderate events in 72% (103/144) and severe events in 41% (59/144). Common AEs included musculoskeletal deformity, muscle weakness, decreased range of motion, gait disturbance, pain, and unequal limb length. HR-QoL scores were lower across all domains compared to the general population, with a high AE burden associated with poorer HR-QoL (B = -8.7, 95% CI -16.8 to -0.7, p = 0.035). Interpretation: The multidisciplinary follow-up care achieved high patient satisfaction and substantial care output, while enabling expert-led, high-quality data collection. The high prevalence of local therapy-related AEs and reduced HR-QoL are important to consider in follow-up and shared decision-making for local therapy in future patients. This multidisciplinary framework is broadly applicable to oncology patients facing treatment-related challenges, with the potential to improve outcomes and advance oncology research and practice. Funding: No specific funding was received for this study.

Indexed as

Long term adverse effectsNeoplasms, bone tissueOutcome assessment, healthcareQuality of life

Identifiers

PMID41278240
PMCPMC12636288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.